Insider Selling: Annexon, Inc. (NASDAQ:ANNX) CEO Sells 5,021 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 5,021 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $2.95, for a total value of $14,811.95. Following the transaction, the chief executive officer now directly owns 351,554 shares in the company, valued at approximately $1,037,084.30. This represents a 1.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Annexon Trading Down 0.7 %

Shares of NASDAQ ANNX opened at $2.83 on Friday. Annexon, Inc. has a 12-month low of $2.63 and a 12-month high of $8.40. The company has a market cap of $301.66 million, a price-to-earnings ratio of -2.70 and a beta of 1.07. The stock’s 50 day simple moving average is $4.29 and its 200 day simple moving average is $5.57.

Institutional Investors Weigh In On Annexon

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in shares of Annexon during the fourth quarter valued at $59,000. CANADA LIFE ASSURANCE Co bought a new stake in Annexon in the 4th quarter valued at about $77,000. E Fund Management Co. Ltd. boosted its stake in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after purchasing an additional 4,086 shares during the period. Forefront Analytics LLC grew its position in Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after purchasing an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Annexon in the 4th quarter worth about $98,000.

Analyst Ratings Changes

ANNX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon presently has an average rating of “Buy” and a consensus price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.